WO2005047261A1 - Forme cristalline non hygroscopique de gatifloxacine - Google Patents

Forme cristalline non hygroscopique de gatifloxacine Download PDF

Info

Publication number
WO2005047261A1
WO2005047261A1 PCT/IB2004/003600 IB2004003600W WO2005047261A1 WO 2005047261 A1 WO2005047261 A1 WO 2005047261A1 IB 2004003600 W IB2004003600 W IB 2004003600W WO 2005047261 A1 WO2005047261 A1 WO 2005047261A1
Authority
WO
WIPO (PCT)
Prior art keywords
gatifloxacin
methanol
crystalline form
room temperature
crude
Prior art date
Application number
PCT/IB2004/003600
Other languages
English (en)
Inventor
Antonio Cosme Gomez
Javier Villasante Prieto
Francisco Eugenio Palomo Nicolau
Original Assignee
Quimica Sintetica, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quimica Sintetica, S.A. filed Critical Quimica Sintetica, S.A.
Publication of WO2005047261A1 publication Critical patent/WO2005047261A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • This invention relates to a new non-hygroscopic crystalline form of the active pharmaceutical substance gatifloxacin.
  • Gatifloxacin is the international common name of l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7- (3-methyl-l- piperazinyl) -4-oxo-3-quinolinecarboxylic acid of formula (I), which finds application in medicine and is known for its antibiotic activity:
  • European patent application EP-A-230295 discloses the preparation of gatifloxacin, which is isolated in hemihydrate form (1/2 H 2 0) , corresponding to 2.34% in calculated weight of water.
  • European patent application EP-A-805156 discloses a sesquihydrated crystalline form (3/2 H 2 O) of gatifloxacin, corresponding to 6.72% in calculated weight of water. Both crystalline forms have a tendency to absorb water and to give rise to other forms with a higher content in hydration water.
  • Patent application WO-A-0222126 discloses gatifloxacin pentahydrate (5 H 2 0) , corresponding to 19.3% in calculated weight of water.
  • the object of the present invention is a new non- hygroscopic crystalline form of gatifloxacin named form II gatifloxacin. Also object of this invention is a process for preparing form II gatifloxacin. Also forming part of this invention is the use of form II gatifloxacin for the manufacture of a medicament for the treatment of infectious diseases of bacterial origin.
  • Figure 1 shows the powder X-ray diffractogram of form II gatifloxacin.
  • Figure 2 shows the powder X-ray diffractogram of gatifloxacin pentahydrate .
  • Figure 3 shows the powder X-ray diffractogram of gatifloxacin sesquihydrate.
  • Figure 4 shows the powder X-ray diffractogram of gatifloxacin hemihydrate, taken from North American patent US5880283. Said patent includes only the X-ray diffractogram, without the corresponding list of peaks at the different 2 ⁇ angles.
  • Figure 5 shows the infrared spectrum recorded on
  • Figure 6 shows the infrared spectrum recorded on KBr tablet of gatifloxacin pentahydrate.
  • Figure 7 shows the infrared spectrum recorded on KBr tablet of gatifloxacin sesquihydrate.
  • Figure 8 shows the infrared spectrum recorded on KBr tablet of gatifloxacin hemihydrate, taken from North American patent US5880283.
  • Figure 9 shows the 13 C nuclear magnetic resonance spectrum of the new non-hygroscopic crystalline form of gatifloxacin.
  • non-hygroscopic crystalline form of gatifloxacin which have been named form II by the authors of this invention and which contains between 8 and 9% by weight of water.
  • the new non-hygroscopic crystalline form of gatifloxacin is characterised by a powder X-ray diffractogram which is different from the powder X-ray diffractograms of the other known forms of gatifloxacin, as can be seen from Figures 1, 2, 3 and 4.
  • the powder X-ray diffractogram of gatifloxacin pentahydrate ( Figure 2) was recorded on the basis of the product prepared according to the method of preparation of gatifloxacin pentahydrate described in Example 1 of patent application WO-A-0222126.
  • the powder diffractogram of gatifloxacin sesquihydrate ( Figure 3) was recorded on the basis of the product prepared according to the method of preparation of gatifloxacin sesquihydrate found in Example 1 of patent application EP-A-805156.
  • the X-ray diffractogram of the hemihydrate form ( Figure 4) is that disclosed in the specification of North
  • the new non-hygroscopic crystalline form of gatifloxacin, object of the invention has a powder X - ray diffractogram that shows peaks with a relative intensity higher than 5%, at the following 2 ⁇ angles:
  • a PHILIPS X'Pert model automatic diffractometer equipped with a Cu tube and a graphite secondary monochromator was used, with the following technical specifications : - K ⁇ Cu wavelength: 1.5419 A; - receiving slit: 0.1 mm; Soller: 0.04 radians; dispersion slit and divergence slit: 1°
  • the tube works at 40 kV and 50 mA. Sweeping was carried out continuously at the 2 ⁇ interval between 5 and 40° with 0.03° pass and 1-second pass time.
  • the new non-hygroscopic crystalline form of gatifloxacin is also characterised by its infrared spectrum recorded on potassium bromide tablet, which is different from the spectrums of the other known forms of gatifloxacin, as shown by Figures 5, 6, 7 and 8.
  • the infrared spectrum of gatifloxacin pentahydrate ( Figure 6) has been recorded on potassium bromide tablet on the basis of the product prepared according to the method of preparation of gatifloxacin pentahydrate described in Example 1 of patent application WO-A-0222126.
  • the non-hygroscopic crystalline form of gatifloxacin object of the invention can be obtained by means of a process that includes the following steps : the crude gatifloxacin is dissolved in methanol by heating to reflux temperature, it is cooled slowly to room temperature under stirring, and - it is kept at rest at room temperature for a period of time between 8 and 14 hours.
  • the initial crude gatifloxacin can be prepared according to the process described in Example 3 of European patent application EP-A-230295.
  • the solution of crude gatifloxacin in methanol at reflux is preferably prepared by using between 50 and 55 volumes of methanol for each unit by weight of crude gatifloxacin.
  • the solution is cooled slowly from the reflux temperature of the methanol down to room temperature. This slow cooling, which is necessary for obtaining the crystalline form of gatifloxacin object of the invention, is preferably carried out for approximately five hours . Crystallisation of the product begins over this period of time.
  • the suspension containing the solid is kept at rest (without stirring) at room temperature for a period of time between 8 and 14 hours . This period of time is necessary for obtaining the crystalline form object of the invention.
  • the form II gatifloxacin can be used for seeding in the cooling stage from the reflux temperature of the methanol down to room temperature, thereby facilitating the formation of crystals .
  • the seeding process is carried out every 2° C from a temperature of 60° C until the seeding amount is inconsiderable when compared with the amount of product crystallised.
  • the method for obtaining the new non-hygroscopic form of gatifloxacin can be completed with the following steps: - the suspension is cooled with stirring to a temperature between 0° C and 5° C, the solid product is filtered, and the product is dried in an oven in vacuo.
  • the cooling of the suspension at a temperature ranging between 0° C and 5° C is carried out by refrigeration with cold water and with stirring, and said temperature is maintained for at least 1 hour.
  • the solid is filtered and washed with cold methanol .
  • the moist solid is dried at 40° C in vacuo for 6 hours and, once cold, is left in contact with the atmosphere at room temperature until it reaches a water content by weight between 8 and 9%.
  • the new non-hygroscopic crystalline form of gatifloxacin obtained according to this process remains stable in its water content for at least 3 months, even at room temperature and in contact with the atmosphere.
  • the new crystalline form of gatifloxacin is characterised by its powder X-ray diffractogram, infrared spectroscopy on potassium bromide tablet, 13 C nuclear magnetic resonance and water analysis using the Karl- Fischer method.
  • the new crystalline form of gatifloxacin which contains between 8 and 9% in weight of water is not hygroscopic, as its water content remains stable for at least 3 months, even at room temperature and in contact with the atmosphere, and it has excellent properties of disintegration and dissolution rate, which make it very well-suited for use as an active substance in the preparation of pharmaceutical formulations, preferably for the manufacture of a medicament for the treatment of infectious diseases of bacterial origin.
  • the example that follows below is disclosed for the purpose of providing a detailed explanation of a specific embodiment of the process of preparation to those skilled in the art in order to yield the compound of the invention.
  • Example 1 Preparing form II gatifloxacin 35.9 g of crude gatifloxacin with a water content of 2.74% by weight is dissolved in 1805 mL of methanol (approximately 50 mL of methanol per gram of crude gatifloxacin) at reflux temperature. The solution obtained is left to cool slowly for approximately 5 hours under stirring. During this period, precipitation of the product starts. The resulting suspension is kept for a further 12 hours at room temperature and without stirring. Subsequently, stirring is recommenced, it is cooled to a temperature between 0 and 5° C over a water/ice bath for approximately 1 hour and filtered through a Buchner funnel .
  • the product retained in the filter is washed with 35 mL of cold methanol and dried in an oven In vacuo at 40° C for approximately 6 hours .
  • the product is then left to dry in a desiccator In vacuo for 45 minutes and the vacuum is broken with nitrogen. 32.9 g of a white solid is obtained, having a water content when it is taken out of the desiccator of 3.45% by weight.
  • the product is kept at room temperature and in contact with the atmosphere, and after three days has a water content of 8.35% by weight, which remains stable for at least 3 months under those conditions.
  • Example 2 Preparing form II gatifloxacin with seeding of crystals 10 g of crude gatifloxacin with a water content of 3.70% by weight are added to 500 mL methanol (solvent to solute ratio: 50 mL of methanol per gram of crude gatifloxacin) and heated to reflux temperature. Once the reflux temperature has been reached, a further 20 mL of methanol are added in order to achieve total dissolution of the product (solvent to solute ratio: 52 mL of methanol per gram of crude gatifloxacin) . The solution obtained is left to cool slowly for approximately 5 hours under stirring.
  • seeding with crystals of form II gatifloxacin is carried out every 2° C from a temperature of 60° C.
  • the resulting suspension is kept for a further 12 hours at rest at room temperature.
  • stirring is recommenced, it is cooled to a temperature ranging between 0 and 5° C over a water/ice bath for approximately 1 hour and filtered through a Buchner funnel.
  • the product retained in the filter is washed with cold methanol (2 x 10 mL) and dried in an oven in vacuo at 40° C for approximately 6 hours.
  • the product is then left to cool in a desiccator in vacuo for 45 minutes and the vacuum is broken with nitrogen.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une forme cristalline non hygroscopique de gatifloxacine qui contient un poids en eau compris entre 8 et 9%, à son procédé de préparation et à son utilisation comme principe actif dans la préparation de formulations pharmaceutiques.
PCT/IB2004/003600 2003-11-13 2004-11-05 Forme cristalline non hygroscopique de gatifloxacine WO2005047261A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP-200302642 2003-11-13
ES200302642A ES2232310B1 (es) 2003-11-13 2003-11-13 Formula cristalina no higroscopica de gatifloxacino.

Publications (1)

Publication Number Publication Date
WO2005047261A1 true WO2005047261A1 (fr) 2005-05-26

Family

ID=34586126

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/003600 WO2005047261A1 (fr) 2003-11-13 2004-11-05 Forme cristalline non hygroscopique de gatifloxacine

Country Status (2)

Country Link
ES (1) ES2232310B1 (fr)
WO (1) WO2005047261A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0805156A1 (fr) * 1994-12-21 1997-11-05 Kyorin Pharmaceutical Co., Ltd. Hydrate d'acide 8-alcoxyquinolonecarboxylique ayant une excellente stabilite et procede de fabrication
WO2002022126A1 (fr) * 2000-09-13 2002-03-21 Bristol-Myers Squibb Company Pentahydrate de gatifloxacine
WO2003086402A1 (fr) * 2002-04-08 2003-10-23 Dr. Reddy's Laboratories Limited Formes cristallines anhydres i et ii de l'acide 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl) 4-oxo-l, 4-dihydroquinoleine-3-carboxylique (gatifloxacine)
WO2003094919A2 (fr) * 2002-05-10 2003-11-20 Teva Pharmaceutical Industries Ltd. Nouvelles formes cristallines de gatifloxacine
WO2004087688A1 (fr) * 2003-04-02 2004-10-14 Hetero Drugs Limited Nouvelles formes cristallines de gatifloxacine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0805156A1 (fr) * 1994-12-21 1997-11-05 Kyorin Pharmaceutical Co., Ltd. Hydrate d'acide 8-alcoxyquinolonecarboxylique ayant une excellente stabilite et procede de fabrication
WO2002022126A1 (fr) * 2000-09-13 2002-03-21 Bristol-Myers Squibb Company Pentahydrate de gatifloxacine
WO2003086402A1 (fr) * 2002-04-08 2003-10-23 Dr. Reddy's Laboratories Limited Formes cristallines anhydres i et ii de l'acide 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl) 4-oxo-l, 4-dihydroquinoleine-3-carboxylique (gatifloxacine)
WO2003094919A2 (fr) * 2002-05-10 2003-11-20 Teva Pharmaceutical Industries Ltd. Nouvelles formes cristallines de gatifloxacine
WO2004087688A1 (fr) * 2003-04-02 2004-10-14 Hetero Drugs Limited Nouvelles formes cristallines de gatifloxacine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRITAIN ET AL: "Polymorphism in Pharmaceutical Solids passage", POLYMORPHISM IN PHARMACEUTICAL SOLIDS, XX, XX, 1999, pages 235 - 238, XP002278123 *
CAIRA M R: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1998, pages 163 - 208, XP001156954, ISSN: 0340-1022 *

Also Published As

Publication number Publication date
ES2232310A1 (es) 2005-05-16
ES2232310B1 (es) 2006-08-01

Similar Documents

Publication Publication Date Title
JP5774732B2 (ja) モキシフロキサシン塩酸塩の合成方法
EP1615645B1 (fr) Forme cristalline iii de chlorhydrate de moxifloxacine anhydre et procede de preparation de cette derniere
TWI519532B (zh) （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體
KR20160003899A (ko) 마크롤리드 고체상 형태
EP0579681B1 (fr) Monohydrate d'hydrochlorure de tiagabine cristalline, sa preparation et son utilisation
KR20040104677A (ko) 신규의 온단세트론 결정 형태, 그 제조 방법, 그 신규의결정 형태를 함유하는 약학 조성물 및 이들을 이용한구역질 치료 방법
KR100740950B1 (ko) 8-시아노-1-사이클로프로필-7-(1ｓ,6ｓ-2,8-디아자비사이클로[4.3.0]노난-8-일)-6-플루오로-1,4-디하이드로-4-옥소-3-퀴놀린 카복실산의 결정 개질체 ｂ
KR20010040711A (ko) 파록세틴의 염
WO2005047261A1 (fr) Forme cristalline non hygroscopique de gatifloxacine
JP2676521B2 (ja) キノロンカルボン酸化合物ｉ型結晶の製造法
CA2131761C (fr) Cristaux produits de derives de l'acide pyridonecarboxylique
EP3004103A1 (fr) Forme cristalline de n,n-dicyclopropyl-4-(1,5-diméthyl-1h-pyrazol-3-ylamino)-6-éthyl-1-méthyl-1,6-dihydro-imidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide pour le traitement de troubles myéloprolifératifs
KR100740947B1 (ko) 8-시아노-1-사이클로프로필-7-(1ｓ,6ｓ-2,8-디아자비사이클로[4.3.0]노난-8-일)-6-플루오로-1,4-디하이드로-4-옥소-3-퀴놀린 카복실산의 결정 개질체 ａ
EP1463712A1 (fr) Nouvelles formes cristallines anhydres de gabapentine
EP0364943A2 (fr) Composés benzohétérocycliques
US20070032505A1 (en) Crystalline form of gatifloxacin
US20040053967A1 (en) 3-(3-Amidinophenyl)-5-[({[1-(1-(iminoethyl)-4-piperidyl}amino)methyl]benzoic acid dihydrochloride and process for preparing the same
CA2576307A1 (fr) Formes cristallines de vitamine d<sb>2</sb>1,24(s)-dihydroxy
JP2002538158A (ja) ８−シアノ−１−シクロプロピル−７−（１ｓ，６ｓ−２，８−ジアザビシクロ−［４．３．０］ノナン−８−イル）−６−フルオロ−１，４−ジヒドロ−４−オキソ−３−キノリンカルボン酸の結晶変態ｃ
JP2012197275A (ja) 結晶性レボホリン酸及びその調製方法
JP5698226B2 (ja) ２’−｛［２−（４−メトキシ−フェニル）−アセチルアミノ］−メチル｝−ビフェニル−２−カルボン酸（２−ピリジン−３−イル−エチル）−アミドの結晶相
WO2022081502A1 (fr) Formes à l'état solide de lorécivivint
WO2000008016A1 (fr) Sels de paroxetine
KR20070030962A (ko) 신규의 온단세트론 결정 형태의 제조 방법
JP2014518236A (ja) ６−（ピペリジン−４−イルオキシ）−２ｈ−イソキノリン−１−オン塩酸塩の多形体

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURUANT TO RULE 69(1) EPC, FORM 1205A DATED 23.10.2006

122 Ep: pct application non-entry in european phase